Skip to main content
. Author manuscript; available in PMC: 2009 Jun 9.
Published in final edited form as: Am J Clin Oncol. 2008 Dec;31(6):573–579. doi: 10.1097/COC.0b013e318173a536

Table 4.

Changes in select immune cell subsets demonstrating at least 2-fold change (pre vs post treatment measurements)

Dose level Percent positive cells
CD3/69 CD11c/CD80 CD11c/CD83 CD11c/CD86 CD40/DR
500
(n=2) 		0.21 ↑ 0.44 0.01 ↑ 0.02 0.03 ↑ 0.12 0.24 ↑ 0.83
750
(n=2) 		0.03 ↑ 0.16
1000
(n=4) 		0.24 ↑ 0.83
0.25 ↑ 0.74		 0.14 ↑ 0.93
1250
(n=2) 		0.03 ↑ 0.07 0.01 ↑ 0.03
1500
(n=3) 		0.01 ↑ 0.04 0.02 ↑ 0.05 0.20 ↑ 0.58 0.09 ↑ 0.27
0.13 ↑ 0.96
1750
(n=4) 		0.04 ↑ 0.10 0.01 ↑ 0.02 0.02 ↑ 0.06
0.07 ↑ 0.20
2000
(n=5) 		0.04 ↑ 0.14
0.12 ↑ 0.54		 0.01 ↑ 0.03 0.16 ↑ 0.64
0.27 ↑ 0.75
0.33 ↑ 0.85		 0.13 ↑ 0.39
0.20 ↑ 0.70